 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the risk[0m
[34mof angioedema?[0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the risk[0m
[32mof angioedema?[0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"EXTENDED PHENYTOIN SODIUM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            No extracts found! You can try doing a web search with the[0m
[31m            `relevant_search_extracts` or `drug_category_search`[0m
[31m            tools/function-calls.[0m
[31m            [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"EXTENDED PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: EXTENDED PHENYTOIN SODIUM: information_for_patients: Suicidal Ideation and Behavior Counsel patients, their caregivers, and families that AEDs, including extended phenytoin sodium capsules, [0m
[31mmay increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or [0m
[31mthe emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers [0m[31m . Serious Dermatologic Reactions Advise patients[0m
[31mof the early signs and symptoms of severe cutaneous adverse reactions and to report any occurrence immediately to a physician [0m[31m . EXTENDED PHENYTOIN SODIUM: information_for_patients: Potential Signs of[0m
[31mDrug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m and Other Systemic Reactions Advise patients of the early toxic signs and symptoms of potential hematologic, dermatologic, [0m
[31mhypersensitivity, or hepatic reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy, facial swelling, and [0m
[31mpetechial or purpuric hemorrhage, and in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. Advise the patient that, because these signs and symptoms may signal a serious reaction, [0m
[31mthat they must report any occurrence immediately to a physician. In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use [0m[31m . [0m
[31mCardiac Effects Counsel patients that cases of bradycardia and cardiac arrest have been reported, both at recommended phenytoin doses and levels, and in association with phenytoin toxicity. Patients [0m
[31mshould report cardiac signs or symptoms to their healthcare provider [0m[31m . Angioedema Advise patients to discontinue phenytoin sodium and seek immediate medical care if they develop signs or symptoms of [0m
[31mangioedema, such as facial, perioral, or upper airway swelling [0m[31m . Effects of Alcohol Use and Other Drugs and Over-the-Counter Drug Interactions Caution patients against the use of other drugs or [0m
[31malcoholic beverages without first seeking their physicianâ€™s advice [0m[1;31m[[0m[31m Drug Interactions [0m[1;31m([0m[1;31m7.1[0m[31m , [0m[1;31m7.2[0m[31m [0m[1;31m)[0m[1;31m][0m[31m . Inform patients that certain over-the-counter medications [0m[1;31m([0m[31me.g. EXTENDED PHENYTOIN SODIUM: [0m
[31minformation_for_patients: antacids, cimetidine, and omeprazole[0m[1;31m)[0m[31m, vitamins [0m[1;31m([0m[31me.g., folic acid[0m[1;31m)[0m[31m, and herbal supplements [0m[1;31m([0m[31me.g., St. Johnâ€™s wort[0m[1;31m)[0m[31m can alter their phenytoin levels. Hyperglycemia Advise [0m
[31mpatients that phenytoin may cause an increase in blood glucose levels [0m[31m . Gingival Hyperplasia Advise patients of the importance of good dental hygiene in order to minimize the development of gingival [0m
[31mhyperplasia and its complications. Neurologic Effects Counsel patients that phenytoin may cause dizziness, gait disturbance, decreased coordination and somnolence. Advise patients taking phenytoin not[0m
[31mto drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects associated with phenytoin. EXTENDED PHENYTOIN SODIUM: [0m
[31minformation_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, including an increased risk for cleft [0m
[31mlip and/or cleft palate [0m[1;31m([0m[31moral clefts[0m[1;31m)[0m[31m, cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits. When [0m
[31mappropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who are not planning a pregnancy to use effective [0m
[31mcontraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy [0m[31m. Instruct patients to notify their physician if they become pregnant or [0m
[31mintend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy [0m[31m .         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Withdrawal Precipitated Seizure: May precipitate status epilepticus. Dose reductions or discontinuation should be [0m
[31mdone gradually. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Suicidal Behavior and Ideation: Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. [0m[1;31m([0m[31m [0m
[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Serious Dermatologic Reactions: Discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not [0m
[31mbe resumed and alternative therapy should be considered. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity: If signs or symptoms of hypersensitivity are[0m
[31mpresent, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Cardiac Effects: Bradycardia and [0m
[31mcardiac arrest have been reported. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m Angioedema: Discontinue immediately if symptoms of angioedema such as facial, perioral, or upper airway swelling occur. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Hepatic Injury: Cases of [0m
[31macute hepatotoxicity have been reported with phenytoin. If this occurs, immediately discontinue. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Hematopoietic Complications: If occurs, follow-up observation is indicated and an [0m
[31malternative antiepileptic treatment should be used. [0m[1;31m([0m[31m [0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Withdrawal Precipitated Seizure, Status Epilepticus Abrupt withdrawal of phenytoin in epileptic patients may precipitate status [0m
[31mepilepticus. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative anticonvulsant [0m
[31mmedication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. In this case, [0m
[31malternative therapy should be an anticonvulsant drug not belonging to the hydantoin chemical class. [0m[1;31m5.2[0m[31m Suicidal Behavior and Ideation Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including phenytoin sodium, increase [0m
[31mthe risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of [0m
[31mdepression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m
[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal [0m
[31mthinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among[0m
[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m%, compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m [0m
[31mpatients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on [0m
[31msuicide.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide: MEDICATION GUIDE Dispense with Medication Guide available at: documents.amneal.com/mg/extended-phenytoin-sodium.pdf Extended phenytoin sodium [0m[1;31m([0m[31mfenâ€˜ i [0m
[31mtoyn soeâ€˜ dee um[0m[1;31m)[0m[31m capsules What is the most important information I should know about extended phenytoin sodium capsules? [0m[1;31m1[0m[31m. Do not stop taking extended phenytoin sodium capsules without first talking[0m
[31mto your healthcare provider. Stopping extended phenytoin sodium capsules suddenly can cause serious problems. Stopping a seizure medicine suddenly can cause you to have seizures more often or seizures[0m
[31mthat will not stop [0m[1;31m([0m[31mstatus epilepticus[0m[1;31m)[0m[31m. [0m[1;31m2[0m[31m. Like other antiepileptic drugs, extended phenytoin sodium capsules may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. [0m
[31mEXTENDED PHENYTOIN SODIUM: spl_medguide: Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: Thoughts about suicide or dying New [0m
[31mor worse anxiety Trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m Acting on dangerous impulses Attempts to commit suicide Feeling agitated or restless New or worse irritability An extreme increase in activity and talking [0m
[1;31m([0m[31mmania[0m[1;31m)[0m[31m New or worse depression Panic attacks Acting aggressive, being angry, or violent Other unusual changes in behavior or mood Suicidal thoughts or actions can be caused by things other than [0m
[31mmedicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any [0m
[31mchanges, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as [0m
[31mneeded, especially if you are worried about symptoms. [0m[1;31m3[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can cause a type of serious allergic reaction that may affect [0m
[31mdifferent parts of the body such as your liver, kidneys, blood, heart, skin or other parts of your body. These can be very serious and cause death. Call your healthcare provider right away if you have[0m
[31many or all of these symptoms: Fever Sore throat Not wanting to eat [0m[1;31m([0m[31manorexia[0m[1;31m)[0m[31m Rash Sores in your mouth Nausea Swollen lymph glands Bruise easily Vomiting Swelling of your face, eye, lips, or tongue [0m
[31mTrouble swallowing or breathing Purple or red spots on your skin Increase infections Yellowing of the skin and the white part of your eyes [0m[1;31m([0m[31mjaundice[0m[1;31m)[0m[31m Call your healthcare provider even if the symptoms[0m
[31mare mild or if you have been taking extended phenytoin sodium capsules for an extended period of time. These symptoms can be a sign of a serious allergic reaction. [0m[1;31m4[0m[31m. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: Extended phenytoin sodium capsules can cause problems with your heart, including a slow heartbeat. Let your healthcare provider know right away if you have any of these symptoms: [0m
[31mdizziness tiredness feeling like your heart is beating slowly or skipping beats chest pain What are extended phenytoin sodium capsules? Extended phenytoin sodium capsules are a prescription medicine [0m
[31mused to treat certain types of seizures called tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures. Do not take extended phenytoin sodium capsules if you: Are allergic to phenytoin or [0m
[31many of the ingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules. Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Have had liver problems from taking phenytoin. Take delavirdine. Before taking [0m
[31mextended phenytoin sodium capsules, tell your healthcare provider about all of your medical conditions, including if you: Have or have had depression, mood problems, or suicidal thoughts or behavior [0m
[31mHave had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones Have or had liver or kidney problems [0m
[31mHave or had an enzyme problem called porphyria Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m Drink alcohol Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your [0m
[31munborn baby. If you take extended phenytoin sodium capsules during pregnancy, your baby is at risk for serious birth defects. EXTENDED PHENYTOIN SODIUM: spl_medguide: If you become pregnant while [0m
[31mtaking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease, causing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin[0m
[31msodium capsules. If you take extended phenytoin sodium capsules during pregnancy, your baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby[0m
[31mmedicine to prevent this. All women of child-bearing age should talk to their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. If you are of [0m
[31mchildbearing age and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules. Pregnancy Registry: If you become [0m
[31mpregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These medicines can change the [0m
[31mlevels of phenytoin in your blood. Taking extended phenytoin sodium capsules with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines [0m
[31mwithout talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take [0m
[31mextended phenytoin sodium capsules? EXTENDED PHENYTOIN SODIUM: spl_medguide: Take extended phenytoin sodium capsules exactly as your healthcare provider tells you. Your healthcare provider will tell [0m
[31myou how much extended phenytoin sodium capsules to take and when to take it. Your healthcare provider may change your dose if needed. Do not change your dose of extended phenytoin sodium capsules [0m
[31mwithout talking to your healthcare provider. Do not stop taking extended phenytoin sodium capsules without first talking to your healthcare provider. Stopping extended phenytoin sodium capsules [0m
[31msuddenly can cause serious problems. What should I avoid while taking extended phenytoin sodium capsules? Do not drink alcohol while you take extended phenytoin sodium capsules without first talking [0m
[31mto your healthcare provider. Drinking alcohol while taking extended phenytoin sodium capsules may change your blood levels of phenytoin which can cause serious problems. Do not drive, operate heavy [0m
[31mmachinery, or do other dangerous activities until you know how extended phenytoin sodium capsules affects you.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: dosage_and_administration: [0m[1;31m2.2[0m[31m Pediatric Dosage The recommended starting dosage for pediatric patients is [0m[1;31m5[0m[31m mg/kg/day by mouth in two or three equally divided [0m
[31mdoses, with subsequent dosage individualized to a maximum of [0m[1;31m300[0m[31m mg daily in divided doses. A recommended daily maintenance dosage is usually [0m[1;31m4[0m[31m to [0m[1;31m8[0m[31m mg/kg/day in equally divided doses. Children over [0m[1;31m6[0m
[31myears and adolescents may require the minimum adult dosage [0m[1;31m([0m[1;31m300[0m[31m mg/day[0m[1;31m)[0m[31m. [0m[1;31m2.3[0m[31m Dosage Adjustments Dosage should be individualized to provide maximum benefit. In some cases, serum blood level [0m
[31mdeterminations may be necessary for optimal dosage adjustments. Trough levels provide information about clinically effective serum level range and confirm patient compliance, and are obtained just [0m
[31mprior to the patientâ€™s next scheduled dose. Peak levels indicate an individualâ€™s threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. [0m
[31mEXTENDED PHENYTOIN SODIUM: dosage_and_administration: Therapeutic effect without clinical signs of toxicity occurs more often with serum total concentrations between [0m[1;31m10[0m[31m and [0m[1;31m20[0m[31m mcg/mL [0m[1;31m([0m[31munbound [0m
[31mphenytoin concentrations between [0m[1;31m1[0m[31m and [0m[1;31m2[0m[31m mcg/mL[0m[1;31m)[0m[31m, although some mild cases of tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m epilepsy may be controlled with lower serum levels of phenytoin. In patients with renal or [0m
[31mhepatic disease, or in those with hypoalbuminemia, the monitoring of unbound phenytoin concentrations may be more relevant [0m[31m. With recommended dosage, a period of seven to ten days may be required to [0m
[31machieve steady-state blood levels with phenytoin and changes in dosage [0m[1;31m([0m[31mincrease or decrease[0m[1;31m)[0m[31m should not be carried out at intervals shorter than seven to ten days. [0m[1;31m2[0m[31m. EXTENDED PHENYTOIN SODIUM: [0m
[31mdosage_and_administration: [0m[1;31m4[0m[31m Switching Between Phenytoin Formulations The free acid form of phenytoin is used in Phenytoin-[0m[1;31m125[0m[31m Suspension and Phenytoin Infatabs. Phenytoin extended capsules and [0m
[31mparenteral phenytoin are formulated with the sodium salt of phenytoin. Because there is approximately an [0m[1;31m8[0m[31m% increase in drug content with the free acid form over that of the sodium salt, dosage [0m
[31madjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa. [0m[1;31m2[0m[31m. EXTENDED PHENYTOIN [0m
[31mSODIUM: dosage_and_administration: [0m[1;31m5[0m[31m Dosing in Patients with Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic [0m
[31mdisease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients [0m[31m . [0m[1;31m2.6[0m[31m Geriatric Dosage Phenytoin clearance is decreased [0m
[31mslightly in elderly patients and lower or less frequent dosing may be required [0m[31m. [0m[1;31m2.7[0m[31m Dosing during Pregnancy Decreased serum concentrations of phenytoin may occur during pregnancy because of altered [0m
[31mphenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations should be performed during pregnancy, and the phenytoin dosage should be adjusted as necessary. EXTENDED PHENYTOIN [0m
[31mSODIUM: dosage_and_administration: Postpartum restoration of the original dosage will probably be indicated [0m[31m. Because of potential changes in protein binding during pregnancy, the monitoring of [0m
[31mphenytoin serum levels should be based on the unbound fraction.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m
[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures and prevention and treatment of seizures occurring during or following neurosurgery. Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic [0m[1;31m([0m[31mgrand [0m
[31mmal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures and prevention and treatment of seizures occurring during or following neurosurgery.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide_table: content>[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Extended phenytoin sodium capsules are a prescription medicine used to treat certain types of seizures called [0m
[31mtonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not [0m
[31mtake<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Are allergic to phenytoin or any of the [0m
[31mingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>Have had liver problems from taking phenytoin.<[0m[31m/[0m[31mitem[0m[31m><item>Take [0m
[31mdelavirdine.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Before taking<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules, tell your healthcare provider about all of your [0m
[31mmedical conditions, including if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Have or have had depression, mood problems, or suicidal thoughts or [0m
[31mbehavior<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones<[0m[31m/[0m[31mitem[0m[31m><item>Have [0m
[31mor had liver or kidney problems<[0m[31m/[0m[31mitem[0m[31m><item>Have or had an enzyme problem called porphyria<[0m[31m/[0m[31mitem[0m[31m><item>Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>Drink alcohol<[0m[31m/[0m[31mitem[0m[31m><item EXTENDED [0m
[31mPHENYTOIN SODIUM: spl_medguide_table: >Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your unborn baby.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules[0m
[31mduring pregnancy, your baby is at risk for serious birth defects.<[0m[31m/[0m[31mitem[0m[31m><item>If you become pregnant while taking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease,[0m
[31mcausing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules during pregnancy,[0m
[31myour baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby medicine to prevent this.<[0m[31m/[0m[31mitem[0m[31m><item>All women of child-bearing age should talk [0m
[31mto their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>If you are of childbearing [0m
[31mage and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Pregnancy [0m
[31mRegistry:<[0m[31m/[0m[31mcontent[0m[31m>If you become pregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy [0m
[31mRegistry. You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. <[0m[31m/[0m[31mitem[0m[31m><item>Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><[0m[31m/[0m[31mlist[0m[31m><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter [0m
[31mmedicines, vitamins, and herbal supplements. These medicines can change the levels of phenytoin in your blood.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Taking extended phenytoin sodium capsules with certain other [0m
[31mmedicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Know the medicines you take. Keep[0m
[31ma list of them and show it to your healthcare provider and pharmacist when you get a new medicine.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How should I take<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[1;31m>[0m[31mextended phenytoin sodium capsules?         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction with Eosinophilia and Systemic [0m
[31mSymptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including phenytoin sodium. Some of these events have been fatal or [0m
[31mlife-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, [0m
[31mnephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, [0m
[31mother organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not [0m
[31mevident. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin sodium should be discontinued if an alternative[0m
[31metiology for the signs or symptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin sodium and other hydantoins are contraindicated in patients who have experienced phenytoin hypersensitivity [0m[31m . [0m
[31mAdditionally, consider alternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., carbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and oxazolidinediones [0m[1;31m([0m[31me.g., trimethadione[0m[1;31m)[0m[31m in these same [0m
[31mpatients. Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in the patient or immediate family members, consider alternatives to phenytoin sodium. [0m[1;31m5[0m[31m. [0m
[31mEXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m6[0m[31m Cardiac Effects Cases of bradycardia and cardiac arrest have been reported in phenytoin sodium-treated patients, both at recommended phenytoin doses[0m
[31mand levels, and in association with phenytoin toxicity [0m[31m . Most of the reports of cardiac arrest occurred in patients with underlying cardiac disease. [0m[1;31m5.7[0m[31m Angioedema Angioedema has been reported in [0m
[31mpatients treated with phenytoin sodium in the postmarketing setting. Phenytoin sodium should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling [0m
[31moccur. Phenytoin sodium should be discontinued permanently if a clear alternative etiology for the reaction cannot be established. [0m[1;31m5.8[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including [0m
[31minfrequent cases of acute hepatic failure, have been reported with phenytoin sodium. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: These events may be part of the spectrum of DRESS or may occur in[0m
[31misolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges[0m
[31mfrom prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin sodium should be immediately discontinued and not readministered. [0m[1;31m5.9[0m[31m Hematopoietic Complications [0m
[31mHematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin sodium. These have included thrombocytopenia, leukopenia, granulocytopenia, [0m
[31magranulocytosis, and pancytopenia with or without bone marrow suppression. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: There have been a number of reports suggesting a relationship between [0m
[31mphenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkinâ€™s disease. Although a cause and effect [0m
[31mrelationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur[0m
[31mwith or without symptoms and signs of DRESS [0m[31m . In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control [0m
[31musing alternative antiepileptic drugs. [0m[1;31m5.10[0m[31m Effects on Vitamin D and Bone The chronic use of phenytoin in patients with epilepsy has been associated with decreased bone mineral density [0m[1;31m([0m[31mosteopenia, [0m
[31mosteoporosis, and osteomalacia[0m[1;31m)[0m[31m and bone fractures.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Withdrawal Precipitated Seizure, Status [0m
[31mEpilepticus [0m[31m Suicidal Behavior and Ideation [0m[31m Serious Dermatologic Reactions [0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity [0m[31m Hypersensitivity [0m[31m Cardiac [0m
[31mEffects [0m[31m Angioedema [0m[31m Hepatic Injury [0m[31m Hematopoietic Complications [0m[31m Effects on Vitamin D and Bone [0m[31m Exacerbation of Porphyria [0m[31m Teratogenicity and Other Harm to the Newborn [0m[31m Hyperglycemia [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.14[0m[1;31m)[0m[31m [0m[1;31m][0m[31m The following adverse reactions associated with the use of phenytoin were identified in clinical studies or postmarketing reports. Because these reactions are reported [0m
[31mvoluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. EXTENDED PHENYTOIN SODIUM: [0m
[31madverse_reactions: Body as a Whole: Allergic reactions in the form of rash and rarely more serious forms and DRESS have been observed, as has angioedema [0m[31m . Anaphylaxis has also been reported. There [0m
[31mhave also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Digestive System: Acute hepatic failure, toxic hepatitis,[0m
[31mliver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been [0m
[31mreported in association with administration of phenytoin. EXTENDED PHENYTOIN SODIUM: adverse_reactions: These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and [0m
[31mpancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. Lymphadenopathy including [0m
[31mbenign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkinâ€™s disease have been reported [0m[31m . Pure red cell aplasia has also been reported. Laboratory Test Abnormality: Phenytoin may decrease [0m
[31mserum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, sometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in the absence of clinical hypothyroidism. Phenytoin may [0m
[31malso produce lower than normal values for dexamethasone or metyrapone tests. EXTENDED PHENYTOIN SODIUM: adverse_reactions: Phenytoin may cause increased serum levels of glucose [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[1;31m5.14[0m[1;31m)[0m[31m [0m[1;31m][0m[31m , alkaline phosphatase, and gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse reactions encountered with phenytoin therapy are nervous system reactions [0m
[31mand are usually dose-related. Reactions include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor [0m
[31mtwitchings, paresthesias, and headaches have also been observed. There have also been rare reports of phenytoin-induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those [0m
[31minduced by phenothiazine and other neuroleptic drugs.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema. Patients are advised to discontinue phenytoin sodium and seek immediate medical care if they develop signs or symptoms of [0m
[32mangioedema, such as facial, perioral, or upper airway swelling.[0m

[32mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mAngioedema: Discontinue immediately if symptoms of angioedema such as facial, perioral, or upper airway swelling occur[0m[32m...[0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: EXTENDED PHENYTOIN SODIUM can increase the risk of [0m
[34mangioedema. Patients are advised to discontinue phenytoin sodium and seek immediate medical care if they develop signs or symptoms of angioedema, such as facial, perioral, or upper airway swelling.[0m

[34mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mAngioedema: Discontinue immediately if symptoms of angioedema such as facial, perioral, or upper airway swelling occur[0m[34m...[0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if EXTENDED PHENYTOIN SODIUM increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema and that patients are advised to discontinue the medication and seek immediate medical care if they [0m
[32mdevelop signs or symptoms of angioedema."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if EXTENDED PHENYTOIN SODIUM increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema and that patients are advised to discontinue the medication and seek immediate medical care if they [0m
[34mdevelop signs or symptoms of angioedema."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if EXTENDED PHENYTOIN SODIUM increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema and that patients are advised to discontinue the medication and seek immediate medical care if they develop [0m
[31msigns or symptoms of angioedema.[0m
[31m        -----[0m
[31m        Final answer: EXTENDED PHENYTOIN SODIUM can increase the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mEXTENDED PHENYTOIN SODIUM can increase the risk of angioedema. Patients are advised to discontinue the medication and seek immediate medical care if they develop signs or symptoms of angioedema, such [0m
[32mas facial, perioral, or upper airway swelling. This information is based on the EXTENDED PHENYTOIN SODIUM label provided by FDAHandler.[0m
